- Home
- EOG vs REGN Comparison
EOG vs REGN Comparison
Compare EOG & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EOG | REGN |
|---|---|---|
| Founded | 1985 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.1B | 68.8B |
| IPO Year | 2006 | 1995 |
Fundamental Metrics
Financial Performance| Metric | EOG | REGN |
|---|---|---|
| Price | $153.05 | $834.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 25 |
| Target Price | $147.00 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 2.7M | 739.9K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.93% | 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | 8.84 | ★ 18.95 |
| Revenue | ★ $22,632,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $16.48 | $12.45 |
| Revenue Next Year | N/A | $10.13 |
| P/E Ratio | ★ $17.22 | $43.63 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $101.59 | $541.00 |
| 52 Week High | $153.67 | $844.92 |
Technical Indicators
Market Signals| Indicator | EOG | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.32 | 76.50 |
| Support Level | $127.38 | $732.04 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 3.36 | 19.45 |
| MACD | 1.03 | 2.17 |
| Stochastic Oscillator | 95.70 | 87.52 |
Price Performance
Historical ComparisonAbout EOG EOG Resources Inc.
EOG Resources is an oil and gas producer with acreage in several US shale plays, primarily in the Permian Basin and the Eagle Ford. At the end of 2024, it reported net proven reserves of 4.7 billion barrels of oil equivalent. Net production averaged roughly 1,232 thousand barrels of oil equivalent per day in 2025 at a ratio of 69% oil and natural gas liquids and 31% natural gas.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.